NCT06090474

Multiple Dose Study to Evaluate Drug-drug Interactions, Safety and Tolerability of NDC-002 in Healthy Volunteers

An Open-label, One-sequence, Three-period, Multiple-dose Study to Evaluate Drug-drug Interactions, Safety and Tolerability Between NDC-002A/NDC-002B and NDC-002C in Healthy Volunteers

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 33 (actual)
• Sponsor: Dr. Noah Biotech Inc. · Industry
• Sex: All
• Age: 19 Years – 55 Years
• Healthy volunteers: Accepted

Summary

An Open-label, One-sequence, Three-period, Multiple-dose Study to Evaluate Drug-drug Interactions, Safety and Tolerability between NDC-002A/NDC-002B and NDC-002C in Healthy Volunteers

Detailed description

This is an Open-label, One-sequence, Three-period, Multiple-dose Study and the goal of this clinical trial is to evaluate in health Volunteers. The main question\[s\] it aims to answer are: * Drug-drug Interactions * Safety * Tolerability The study consisted of Three-period: Period 1 which repeated administration of NDC-002C for 7 days and Period 2 which repeated administration of NDC-002A for 7 days, followed by administration of NDC-002B for 8 days and Period 3 which repeated concomitant administration of NDC-002B and NDC-002C for 7 days.

Conditions

• Stroke Sequelae
• Stroke

Interventions

Type	Name	Description
DRUG	NDC-002	Combination of NDC-002B and NDC-002C

Timeline

• Start date: 2023-01-12
• Primary completion: 2023-03-15
• Completion: 2023-03-15
• First posted: 2023-10-19
• Last updated: 2023-10-24

Locations

1 site across 1 country: South Korea